Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment

Hidde H. Huidekoper1,2 • Frédéric M. Vaz3 • Aad Verrips4 • Annet M. Bosch2

Received: 20 February 2015 / Revised: 13 June 2015 / Accepted: 16 June 2015 / Published online: 10 July 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract We present a two-week old girl who was diagnosed with cerebrotendinous xanthomatosis (CTX), an inborn error of bile acid synthesis, after a diagnostic workup for convulsions which were shown to be caused by a parechovirus encephalitis. The diagnosis of CTX was confirmed with CYP27A1 mutation analysis. She was started on chenodeoxycholic acid (CDCA) supplementation, which inhibits cholestanol production through a feedback mechanism, at the advised dosage of 15 mg/kg/day. Within 6 weeks, she developed jaundice with hepatomegaly. CDCA supplementation was stopped after which liver size and function rapidly normalised. CDCA supplementation was then restarted and maintained at 5 mg/kg/day. Cholestanol, liver enzymes and total bilirubin were frequently monitored in the patient, who is now 2.8 years of age, and have remained within normal range. Her psychomotor development has been normal.

Conclusion: adequate metabolic control was achieved in an infant with CTX with CDCA supplementation at a dosage of 5 mg/kg/day and was well tolerated. CDCA supplementation at 15 mg/kg/day seems hepatotoxic in infants and should not be used. This is relevant in view of the possible inclusion of CTX in newborn screening programs in the near future.

What is Known:
• Cerebrotendinous xanthomatosis (CTX), an inborn error of bile acid synthesis, is a progressive neurological disorder.
• Symptoms of CTX can be halted, and likely prevented, with chenodeoxycholic acid (CDCA) supplementation, making CTX a good candidate for newborn screening.

What is New:
• CDCA supplementation at the advised dosage of 15 mg/kg/day in children seems hepatotoxic in infants with CTX.
• Adequate metabolic control in an infant with CTX was achieved with CDCA supplementation at 5 mg/kg/day and well tolerated.

Keywords Cerebrotendinous xanthomatosis • Chenodeoxycholic acid • Treatment • Infant • Newborn screening • Hepatotoxicity

Abbreviations
CTX Cerebrotendinous xanthomatosis
CDCA Chenodeoxycholic acid
CA Cholic acid

Introduction
Cerebrotendinous xanthomatosis (CTX) [OMIM #213700] is a rare autosomal recessive disorder of bile acid synthesis caused by the deficiency of the enzyme 27-sterol hydroxylase (CYP27) [EC 1.14.13.15]. This results in a reduced production of chenodeoxycholic acid (CDCA) and cholic acid (CA) and accumulation of cholestanol and cholesterol in different tissues.
Clinical features of CTX include neonatal cholestasis, bilateral cataract and chronic diarrhoea during childhood and tendon xanthomas and various neuropsychiatric symptoms, including pyramidal and cerebellar signs, peripheral neuropathy and dementia, from the second decade onward [10].

The development of these symptoms can be halted or prevented by supplementation of CDCA, which reduces bile acid synthesis via direct inhibition of the enzyme cholesterol-7α-hydroxylase (CYP7A1) [EC 1.14.13.17] and via negative feedback on cholesterol biosynthesis (Fig. 1) [5, 7]. The prognosis of CTX is good when therapy is started early but is less favourable when initiated at a later age [1, 9, 11]. Because early detection and start of treatment likely prevents symptoms, CTX is a good candidate for newborn screening. Although a validated screening method is not yet available, DeBarber et al. recently published a potential screening method for CTX based on the quantification of ketosterols [4].

The advised dosage of CDCA supplementation in children with CTX is 15 mg/kg/day [9]. Here, we describe an infant with CTX who developed toxic hepatitis with CDCA supplementation at this dosage and demonstrate that adequate metabolic control in infants and young children with CTX can also be achieved with the lower dosage of 5 mg/kg/day of CDCA. This is relevant in view of the possible inclusion of CTX in newborn screening programs in the near future.

Case report

A girl, the second child of Dutch, non-consanguineous parents, was born at term after an uneventful pregnancy and delivery with a normal birth weight and normal Apgar scores. At day 8, she presented with feeding difficulties, lethargy and temperature instability, followed by convulsions for which continuous midazolam was started. No jaundice was present at this time. Initial workup, including full blood count, glucose, electrolytes, liver enzymes, coagulation, total bilirubin, C-reactive protein and blood gas analysis, only revealed prolonged coagulation times (PT and aPTT) which could be rapidly corrected with vitamin K. Further diagnostic workup, including blood, urine, faeces and cerebrospinal fluid cultures and viral PCR, a cerebral MRI and metabolic screening of plasma and urine, demonstrated a positive parechovirus PCR in cerebrospinal fluid, blood and faeces, consistent with the diagnosis of parechovirus encephalitis. Bilateral infarction of periventricular white matter without bleeding was shown on the cerebral MRI and was attributed to this encephalitis. After initial treatment on the pediatric intensive care unit, she was transferred to a pediatric ward, where she recovered without any signs of neurological sequelae. After 9 days, the girl was discharged in good clinical condition.

Coincidently, the metabolic screening demonstrated an elevated plasma cholestanol (21.5 μmol/L; reference range (age 0–100 days) 2.8–19.0 μmol/L), a low CDCA (0.1 mmol/L; reference range 0.7–10.0 μmol/L) and CA (0.4 mmol/L; reference range 0.1–4.7 μmol/L) and urinary excretion of the characteristic glucuronic acid conjugates of bile alcohols (cholestanetetrol, pentol and hexol), consistent with the diagnosis of CTX. No other metabolic abnormalities were detected. Mutation analysis of CYP27A1 revealed two known missense mutations, c.1016C>T (p.Thr339Met) and c.1183C>T (p.Arg395Cys) [10], confirming the diagnosis of CTX. The patient was started on CDCA supplementation at the advised dosage of 15 mg/kg/day in three doses in children [9] resulting in the initial normalisation of plasma cholestanol (15.0 μmol/L), but 6 weeks after initiation of therapy, the patient presented with jaundice, pruritis and mild hepatomegaly (liver palpable...
3 cm below right costal margin) without signs of infection. Total bilirubin (73 μmol/L), liver transaminases (ALT 336 U/L; AST 561 U/L) and alkaline phosphatase (647 U/L) were markedly elevated; gamma-glutamyltransferase (68 U/L) and coagulation times (PT 11.2 s; aPTT 20 s) were normal. Viral hepatitis due to an Epstein-Barr virus or cytomegalovirus infection was excluded. CDCA supplementation was stopped to rule out toxic hepatitis. Plasma CDCA concentration at this time was 467 μmol/L. After cessation of CDCA supplementation, liver size normalised within 1 month and liver enzymes returned to normal values within 3 months. CDCA supplementation was restarted at a dosage of 5 mg/kg/day, resulting in the normalisation of plasma cholestanol (reference range (age>100 days) 3.5–10.0 μmol/L) and a plasma CDCA concentration between 6 and 12 μmol/L. The urinary excretion of CTX glucuronic acid conjugates of bile alcohols decreased to almost undetectable. The patient has been maintained on a CDCA dosage of 5 mg/kg/day since, and the plasma cholestanol concentration has remained within the normal range during 2.5 years of treatment. The patient’s growth and psychomotor development have been normal, and no clinical or neurological signs of CTX have been detected until now (she is currently 2.8 years).

Plasma cholestanol, CDCA, ALT and total bilirubin concentrations before CDCA supplementation, during CDCA supplementation at 15 mg/kg/day and 5 mg/kg/day and in the period without treatment are shown in Fig. 2.

Discussion

Cerebrotendinous xanthomatosis (CTX) is a well-established metabolic disorder of bile acid synthesis with serious progressive neurological sequelae without treatment. Supplementation of CDCA has been proven effective in mitigating the symptoms of CTX and will probably prevent the neurological phenotype when treatment is started at an early age [1]. Therefore, CTX is a good candidate for implementation in newborn screening programs. Currently, screening methods are being developed to make this feasible, and it is expected that CTX will be included in newborn screening programs in the near future.

In this report, we demonstrate the development of toxic hepatitis in an infant diagnosed with CTX shortly after birth after starting CDCA supplementation at the advised dosage of 15 mg/kg/day [9]. This is supported by the fact that liver size and function rapidly normalised after cessation of CDCA supplementation during CDCA supplementation at 15 mg/kg/day (dark shaded area), after cessation of CDCA supplementation and during CDCA supplementation at 5 mg/kg/day (light shaded area). The upper limit of normal for each metabolite is also shown (dotted line).
supplementation and that common causes for viral hepatitis in children were ruled out. Hepatitis A to E were not excluded, but it is highly unlikely that either one of these caused the hepatitis as neither the patient nor her mother did receive any blood products, hepatitis A and E are not endemic in The Netherlands, and no trips to foreign countries were undertaken. Furthermore, the potential hepatotoxic effect of CDCA, as well as other bile acids, is well established and has been shown to be dose dependent [8].

Although neonatal cholestasis is part of the clinical spectrum of CTX, it is likely that CTX by itself caused the hepatitis as our patient only developed jaundice after initiation of CDCA supplementation. However, the hepatotoxic effect of CDCA in our patient may have been aggravated by the accumulation of bile acid synthesis intermediates in hepatocytes. This would also explain the observed rise in plasma cholestanol with the development of hepatitis. In support of this is the observation that liver function deteriorated in an infant who presented with giant cell hepatitis and who was started on CDCA supplementation at a dosage of 10 mg/kg/day under suspicion of a bile acid synthesis defect [2]. He was later diagnosed with CTX [3].

It has been proposed that CTX in infants may be best treated with CA supplementation because of the potential hepatotoxic effect of CDCA [6]. However, we think that supplementation of CDCA is the right choice of therapy in CTX, also in infants, as it is a more potent stimulator of the nuclear receptor FXR, thereby effectively inhibiting cholestanol formation through the cholesterol 7α-hydroxylase pathway in CTX [5]. Here, we show that CDCA supplementation at a dosage of 5 mg/kg/day is safe and effective in an infant with CTX.

In this report, we demonstrate that adequate metabolic control in an infant with CTX was achieved with CDCA supplementation at a dosage of 5 mg/kg/day and was well tolerated. The currently advised dosage of 15 mg/kg/day of CDCA seems hepatotoxic in infants and should not be used in young children. This is relevant in view of the possible inclusion of CTX in newborn screening programs in the near future.

Compliance with ethical standards

Informed consent Written informed consent was obtained from both parents.

Conflicts of Interest The authors declare that they have no competing interests.

Funding None to report.

Authors’ contribution HHH for the treatment of patient, data collection and analysis and writing of the manuscript. FMV for the analysis of blood and urine samples, interpretation of data and writing of the manuscript. AV for advising on treatment (clinical expert on CTX), interpretation of data and commenting on the manuscript draft. AMB for supervising treatment, interpretation of data and commenting on the manuscript draft.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falk-Zaccai TC (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147. doi:10.1542/peds.2008-0192
2. Clayton PT, Casteels M, Mieli-Vergani G, Lawson AM (1995) Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis? Pediatri Res 37:424–431. doi:10.1203/00006450-199504000-00007
3. Clayton PT, Verrills A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R (2002) Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25:501–513
4. Debarber AE, Luo J, Star-Weinstock M, Purkayastha S, Geraghty MT, Chiang JP, Merkens LS, Pappu AS, Steiner RD (2014) A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res 55:146–154. doi:10.1194/jlr.P043273
5. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliwer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365–1368
6. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P (2008) Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 31(Suppl 2):S241–S245. doi:10.1016/j.jimd.2008.08-015-z
7. Salen G, Meriwether TW, Nicolau G (1975) Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 14:57–74
8. Song P, Zhang Y, Claassen CD (2011) Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicity in mice. Toxicol Sci 123:359–367. doi:10.1093/toxsci/kfr177
9. van Heijst AF, Verrills A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316
10. Verrills A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabriels FJ, van Engelen BG, van den Heuvel LP (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123(Prt 5):908–919
11. Yahalom G, Taabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropathol 36:78–83. doi:10.1097/WNF.0b013e318288076a